Skip to main content
Predictive Oncology Inc. logo

Predictive Oncology Inc. — Investor Relations & Filings

Ticker · POAI ISIN · US74039M3097 US Professional, scientific and technical activities
Filings indexed 1,215 across all filing types
Latest filing 2026-06-09 Capital/Financing Update
Country US United States of America
Listing US POAI

About Predictive Oncology Inc.

https://predictive-oncology.com/

Predictive Oncology is a science-driven company that applies artificial intelligence (AI) and machine learning to oncology drug discovery and development. The company's core platform integrates its predictive AI engine with a proprietary biobank containing over 150,000 human tumor samples. This enables high-confidence predictions of drug response, helping biopharmaceutical partners de-risk development and select promising drug-tumor combinations in the pre-clinical phase. The company also provides advanced 3D tumor models that mimic the human physiological environment for more clinically relevant testing. Additionally, its clinical laboratory offers tumor drug-response and genomic biomarker testing services to support the personalization of cancer therapies.

Recent filings

Filing Released Lang Actions
FORM S-3
Capital/Financing Update Classification · 75% confidence The document is a Form S-3 Registration Statement and preliminary prospectus filed under the Securities Act of 1933 for Axe Compute Inc. It is clearly a securities offering document (shelf registration for common stock, preferred stock, debt securities, warrants, etc.), not an annual or interim report, audit report, proxy, management change or earnings release. The most appropriate category for a registration/prospectus relating to capital raising activities is Capital/Financing Update (CAP).
2026-06-09 English
FORM 8-K
Regulatory Filings Classification · 82% confidence The document is a Form 8-K Current Report filed under the Securities Exchange Act, describing updated risk factors (Item 8.01), and not containing full financial statements but rather an SEC compliance disclosure. It does not fit into specific categories like earnings release, dividend notice, or annual report. It is a general regulatory filing, so it falls under the fallback category Regulatory Filings (RNS).
2026-06-09 English
FORM 8-K
Earnings Release Classification · 93% confidence The document is a Form 8-K Current Report disclosing Item 2.02 “Results of Operations and Financial Condition” by furnishing a press release announcing the company’s quarterly financial results for the period ended March 31, 2025. It is not the full financial statements, but is the initial announcement of periodic results. This matches the definition of an Earnings Release (ER). Q1 2025
2026-05-15 English
FORM 8-K
Capital/Financing Update Classification · 89% confidence The document is an SEC Form 8-K “Current Report” under Item 8.01 describing the filing of a prospectus supplement amending an at-the-market offering program and updating the amount of shares eligible to be sold and amount sold to date. This constitutes an update on the company’s fundraising/financing activities, which falls squarely into the “Capital/Financing Update” category.
2026-05-15 English
424B5
Capital/Financing Update Classification · 85% confidence The document is a Prospectus Supplement filed pursuant to Rule 424(b)(5) amending and updating the terms of an ATM (At the Market) equity offering. It details the aggregate shares sold, updates on public float, and increases the total amount of common stock available for issuance under the Sales Agreement. This is a financing/raise update rather than a formal annual report, earnings release, or stock split announcement. It fits the Capital/Financing Update category.
2026-05-15 English
FORM 10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.